Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01140217 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception
A Phase 3 study of Contraceptive Usage, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,659
- Enrollment target
- 20
- Study locations
NCT01140217 is a Phase 3 study of Contraceptive Usage that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 1,659 participants, above the 477-participant average among 11 other Contraceptive Usage trials with a reported enrollment target (248% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT01140217, a Phase 3 study of Contraceptive Usage, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,659 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether NEA TDS is effective in the prevention of pregnancy. The safety of this product will also be evaluated.
Conditions Studied
Interventions
- DRUG Norethindrone Acetate
Study Locations (20)
Florida
- Watson Investigational Site - Aventura
- Watson Investigational Site - Daytona Beach
- Watson Investigational Site - Jacksonville
- Watson Investigational Site - Lake Worth
- Watson Investigational Site - Miami
- Watson Investigational Site - North Miami
- Watson Investigational Site - Pinellas Park
- Watson Investigational Site - Sarasota
Alabama
- Watson Investigational Site - Birmingham
- Watson Investigational Site - Mobile
- Watson Investigational Site - Montgomery
California
- Watson Investigational Site - Garden Grove
- Watson Investigational Site - La Mesa
- Watson Investigational Site - San Diego
Arizona
- Watson Investigational Site - Chandler
Arkansas
- Watson Investigational Site - Little Rock
Colorado
- Watson Investigational Site - Denver
Delaware
- Watson Investigational Site - Newark
District of Columbia
- Watson Investigational Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,659 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01140217
The ClinicalTrials.gov registry entry for NCT01140217 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,659 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 477-participant average among 11 other Contraceptive Usage trials with a reported enrollment target (248% higher). The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Contraceptive Usage appearing as the primary indexed condition, and to 1 intervention - of which Norethindrone Acetate is the first listed.
NCT01140217 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT01140217 about?
NCT01140217 is a clinical study titled "Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception". The purpose of this study is to determine whether NEA TDS is effective in the prevention of pregnancy. The safety of this product will also be evaluated.
What is the current status of trial NCT01140217?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,659 participants. The study started on 2010-05. Estimated completion is 2012-03.
What conditions does trial NCT01140217 study?
This clinical trial studies the following conditions: Contraceptive Usage.
What interventions are being tested in trial NCT01140217?
The interventions under investigation include: Norethindrone Acetate (DRUG).
Who is sponsoring clinical trial NCT01140217?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01140217 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraceptive Usage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assess Performance Attributes and Acceptability of Non-medicated Intravaginal Rings Among Sexually Active Women in Atlanta, GA
RECRUITING · Early Phase 1
-
Disparities in Emergency Contraceptive Metabolism Dictate Efficacy
RECRUITING · Phase 4
-
Effectiveness Testing of a Videogame Intervention (No Baby No) to Decrease Contraception Non-use Among Adolescents.
RECRUITING · NA
-
RCT Evaluating Standardized Counseling on Early Discontinuation for Irregular Bleeding in Nexplanon Users
ACTIVE NOT RECRUITING · Phase 4
-
The Over The Counter Pill National Study
ACTIVE NOT RECRUITING
-
Sexual Health Empowerment for Women's Health
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.